Piper Sandler Reiterates Overweight on Fulcrum Therapeutics, Raises Price Target to $23
Benzinga Newsdesk 11 months ago
NewsPrice TargetReiterationAnalyst Ratings
Piper Sandler analyst Edward Tenthoff reiterates Fulcrum Therapeutics (NASDAQ:FULC) with a Overweight and raises the price target from $16 to $23.
Piper Sandler analyst Edward Tenthoff reiterates Fulcrum Therapeutics (NASDAQ:FULC) with a Overweight and raises the price target from $16 to $23.